Breast cancer: statins tied to lower CBC risk, says Danish study

  • Br J Cancer

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Postdiagnosis statin use is associated with a 12% reduction in contralateral breast cancer (CBC) risk in patients with nonmetastatic breast cancer.
  • Patients with estrogen receptor (ER)-negative breast cancer benefit even more.

Why this matters

  • Findings are consistent with earlier epidemiological studies and experimental studies.
  • Findings suggest that clinicians should consider prescribing statins for CBC prevention, especially in ER patients.

Study design

  • Retrospective cohort of 57,723 women with nonmetastatic breast cancer from the Danish Breast Cancer Group database.
  • Postdiagnosis statin use was defined by a minimum of 2 prescriptions 1 year apart.
  • Funding: Danish Cancer Society; private foundations.

Key results

  • Follow-up was 310,537 person-years.
  • Postdiagnosis statin use (vs never-use) was associated with a 12% lower CBC risk (HR, 0.88; 95% CI, 0.73-1.05); current statin use had similarly lower risk (HR, 0.87; 95% CI, 0.72-1.04).
  • Long-term postdiagnosis statin use overall was associated with a 36% lower CBC risk (HR, 0.64; 95% CI, 0.43-0.96), but not long-term consistent use or high-intensity use (HR, 0.95; 95% CI, 0.55-1.64).
  • Among patients with ER− breast cancer, postdiagnosis statin use was associated with a 33% lower CBC risk (HR, 0.67; 95% CI, 0.45-1.00).

Limitations

  • Retrospective, observational design.
  • No information on compliance or other drug use.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit